<DOC>
	<DOC>NCT01147003</DOC>
	<brief_summary>This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.</brief_summary>
	<brief_title>Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<criteria>Outpatients ≥ 50 kg (110 lb) of weight. A diagnosis of epilepsy (≥ 2 years prior to screening) with partial seizures with or without secondarily generalized seizures. Uncontrolled partial seizures despite having been treated with at least two different antiepileptic drugs (AEDs) within the last 2 years prior to screening. At least 4 partial seizures during the 4week baseline period and at least 4 partial seizures during the 4 weeks prior to the baseline period. Cohort 1 patients must be receiving stable treatment with 1 or a maximum of 2 AEDs.Cohort 2 patients must be receiving stable treatment with 1, 2, or 3 AEDs. Presence of only nonmotor simple partial seizures. History of psychogenic seizures. Absences, myoclonic seizures e.g. in the context of primary generalized epilepsy. Previous history of LennoxGastaut syndrome. Status epilepticus or seizure clusters, according to the judgement of the investigator, occurring within 52 weeks prior to randomization. Pregnant or nursing (lactating) women. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Seizure frequency</keyword>
	<keyword>nervous system diseases</keyword>
	<keyword>brain diseases</keyword>
	<keyword>neurologic manifestations</keyword>
	<keyword>adjunctive treatment</keyword>
	<keyword>AEDs</keyword>
	<keyword>antiepileptic drug</keyword>
</DOC>